NYSE:CTLT - Catalent Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $41.81 -0.22 (-0.52 %) (As of 02/19/2019 10:03 AM ET)Previous Close$42.03Today's Range$41.66 - $41.9652-Week Range$29.23 - $46.43Volume26,464 shsAverage Volume1.07 million shsMarket Capitalization$6.09 billionP/E Ratio26.30Dividend YieldN/ABeta1.66 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics and Specialty Drug Delivery segment formulates, develops, and manufactures small molecule and biologic drug products in prefilled syringes, vials and cartridges, blow-fill-seal unit doses, and injectable formats; develops biologic cell lines; manufactures biologic drug substances; and offers bioanalytical development and testing services. The Oral Drug Delivery segment formulates, develops, and manufactures oral dosage forms using proprietary and conventional drug delivery technologies, such as Zydis, OptiDose CR, OptiPact, OptiForm API and Solution Suite, Pharmatek SD Spray Drying, OptiMelt hot melt extrusion, Micron particle size reduction, and FlexDose; and provides stick pack formulation and filling, and analytical development and testing services. The Clinical Supply Services segment offers Manufacturing, packaging, labeling, storage, distribution, and inventory management for drugs and biologics clinical trials; FastChain demand-led clinical supply services; clinical e-solutions and informatics; and comparator sourcing services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was founded in 2007 and is headquartered in Somerset, New Jersey. Receive CTLT News and Ratings via Email Sign-up to receive the latest news and ratings for CTLT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:CTLT Previous Symbol CUSIPN/A Webwww.catalent.com Phone732-537-6200Debt Debt-to-Equity Ratio1.36 Current Ratio2.08 Quick Ratio1.63Price-To-Earnings Trailing P/E Ratio26.30 Forward P/E Ratio24.74 P/E Growth2.26 Sales & Book Value Annual Sales$2.46 billion Price / Sales2.47 Cash Flow$3.0970 per share Price / Cash Flow13.50 Book Value$10.73 per share Price / Book3.90Profitability EPS (Most Recent Fiscal Year)$1.59 Net Income$83.60 million Net Margins5.48% Return on Equity17.42% Return on Assets5.07%Miscellaneous Employees10,700 Outstanding Shares145,633,000Market Cap$6.09 billion OptionableOptionable Catalent (NYSE:CTLT) Frequently Asked Questions What is Catalent's stock symbol? Catalent trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTLT." How were Catalent's earnings last quarter? Catalent Inc (NYSE:CTLT) released its quarterly earnings data on Tuesday, February, 5th. The company reported $0.45 earnings per share for the quarter, topping the consensus estimate of $0.37 by $0.08. The business had revenue of $623 million for the quarter, compared to analyst estimates of $608.38 million. Catalent had a net margin of 5.48% and a return on equity of 17.42%. Catalent's quarterly revenue was up 2.8% compared to the same quarter last year. During the same quarter last year, the firm earned $0.45 EPS. View Catalent's Earnings History. When is Catalent's next earnings date? Catalent is scheduled to release their next quarterly earnings announcement on Tuesday, May 7th 2019. View Earnings Estimates for Catalent. What guidance has Catalent issued on next quarter's earnings? Catalent updated its FY 2019 earnings guidance on Tuesday, February, 5th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $2.5-2.59 billion, compared to the consensus revenue estimate of $2.51 billion. What price target have analysts set for CTLT? 8 analysts have issued 12 month price targets for Catalent's shares. Their predictions range from $43.00 to $55.00. On average, they expect Catalent's stock price to reach $47.5714 in the next year. This suggests a possible upside of 13.8% from the stock's current price. View Analyst Price Targets for Catalent. What is the consensus analysts' recommendation for Catalent? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalent in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Catalent. Has Catalent been receiving favorable news coverage? News articles about CTLT stock have trended positive recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Catalent earned a news sentiment score of 2.2 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the near future. Who are some of Catalent's key competitors? Some companies that are related to Catalent include Teva Pharmaceutical Industries (TEVA), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Mylan (MYL), Ono Pharmaceutical (OPHLF), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), Sarepta Therapeutics (SRPT), Genmab A/S (GNMSF), Bausch Health Companies (BHC), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), Beigene (BGNE), Jazz Pharmaceuticals (JAZZ) and SAGE Therapeutics (SAGE). Who are Catalent's key executives? Catalent's management team includes the folowing people: Mr. John R. Chiminski, Chairman, Pres & CEO (Age 55)Mr. Wetteny N. Joseph, Sr. VP & CFO (Age 47)Mr. Steven L. Fasman, Sr. VP, Gen. Counsel & Corp. Sec. (Age 56)Mr. William Downie, Sr. VP of Global Marketing & Sales (Age 52)Mr. Jonathan Arnold, Pres of Oral Drug Delivery Bus. Unit (Age 53) Who are Catalent's major shareholders? Catalent's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.85%), Brown Advisory Inc. (1.98%), D. E. Shaw & Co. Inc. (1.63%), GW&K Investment Management LLC (1.27%), Oregon Public Employees Retirement Fund (1.24%) and Macquarie Group Ltd. (1.22%). Company insiders that own Catalent stock include Barry Littlejohns, Christine Dolan, Donald E Morel, Jr, John J Greisch, John R Chiminski, Lance Miyamoto, Sharon Johnson, Steven L Fasman, Uwe Roehrhoff and William Downie. View Institutional Ownership Trends for Catalent. Which institutional investors are selling Catalent stock? CTLT stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Macquarie Group Ltd., Westfield Capital Management Co. LP, Impax Asset Management Group plc, Bank of America Corp DE, Bank of New York Mellon Corp, SG Americas Securities LLC and Colony Group LLC. Company insiders that have sold Catalent company stock in the last year include Barry Littlejohns, John R Chiminski, Lance Miyamoto, Steven L Fasman and William Downie. View Insider Buying and Selling for Catalent. Which institutional investors are buying Catalent stock? CTLT stock was bought by a variety of institutional investors in the last quarter, including Oregon Public Employees Retirement Fund, Jennison Associates LLC, D. E. Shaw & Co. Inc., First Trust Advisors LP, Brown Advisory Inc., BlackRock Inc., Forsta AP Fonden and Geode Capital Management LLC. Company insiders that have bought Catalent stock in the last two years include Donald E Morel, Jr, John J Greisch and Uwe Roehrhoff. View Insider Buying and Selling for Catalent. How do I buy shares of Catalent? Shares of CTLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Catalent's stock price today? One share of CTLT stock can currently be purchased for approximately $41.81. How big of a company is Catalent? Catalent has a market capitalization of $6.09 billion and generates $2.46 billion in revenue each year. The company earns $83.60 million in net income (profit) each year or $1.59 on an earnings per share basis. Catalent employs 10,700 workers across the globe. What is Catalent's official website? The official website for Catalent is http://www.catalent.com. How can I contact Catalent? Catalent's mailing address is 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873. The company can be reached via phone at 732-537-6200 or via email at [email protected] MarketBeat Community Rating for Catalent (NYSE CTLT)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 435 (Vote Outperform)Underperform Votes: 491 (Vote Underperform)Total Votes: 926MarketBeat's community ratings are surveys of what our community members think about Catalent and other stocks. Vote "Outperform" if you believe CTLT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTLT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/19/2019 by MarketBeat.com StaffFeatured Article: How is an ETF different from a mutual fund?